banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Inna  Fedorenko

Inna Fedorenko

Inna Fedorenko

  

Bio

fiogf49gjkf0d

Dr. Inna Fedorenko is shown with her committee following her successful dissertation defense on July 2, 2014. Pictured from left are committee member Jeffrey Weber, major professor Keiran Smalley, Inna, invited chair Ashani Weeraratna from The Wistar Institute, committee members Eric Haura and Gary Reuther.

Dr. Fedorenko has accepted a position with Dr. Smalley as a postdoctoral fellow.

Dr. Fedorenko's publication record while in the Program:

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. BR J Cancer. 2010 Jun 8; 102(12): 1724-30

Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011 Aug 1;82(3):201-9.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS.PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.Cancer Res. 2011 Apr 1;71(7):2750-60.

Fedorenko IV, Gibney GT, Smalley KS.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Oncogene. 2012 Oct 15. doi: 10.1038/onc.2012.453.PMID: 23069660

Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KSM. Paradoxical oncogenesis- the long-term effects of BRAF inhibition in melanoma. Nature Reviews Clinical Oncology. 2013 May 28; Advance online publication doi:10.1038/nrclinonc.2013.83

Pimiento JM, Larkin EM, Smalley KS, Wiersma GL, Monks NR, Fedorenko IV, Peterson CA, Nickoloff BJ. Melanoma genotypes and phenotypes get personal.Lab Invest. 2013 Aug;93(8):858-67. doi: 10.1038/labinvest.2013.84. Epub 2013 Jul 1.PMID:23817084

Kim E, Rebecca V, Fedorenko IV, Messina JL, Mathew R, Maria-Engler SS, Basanta D, Smalley KS, Anderson AR.Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach.Cancer Res. 2013 Dec 1;73(23):6874-85.PMID:24080279

Sloot S,Fedorenko IV, Smalley KS, Gibney GT.Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?Expert Opin Pharmacother. 2014 Apr;15(5):589-92.PMID:24456413

Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amaravadi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS.Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.Pigment Cell Melanoma Res. 2014 May;27(3):465-78. PMID:24490764

Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS.Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics.Mol Cell Proteomics. 2014 Apr 23.PMID:24760959

Dr. Fedorenko's publication record since graduation:

Fedorenko IV, Smalley KS. The complexity of microenvironment-mediated drug resistance. Genes Cancer. 2015 Sep;6(9-10):367-8. PMID: 26622938

Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KS. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.J Invest Dermatol. 2015 Dec;135(12):3115-24. PMID: 26302068

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. ibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016 Mar 10;35(10):1225-35. PMID: 26073081

Phadke M, Gibney GT, Rich CJ, Fedorenko IV, Chen YA, Kudchadkar RR, Sondak VK, Weber J, Messina JL, Smalley KS. XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. J Invest Dermatol. 2015 Oct;135(10):2542-4. doi: 10.1038/jid.2015.205. Epub 2015 Jun 3. No abstract available. PMID: 26039542

Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KS. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol. 2015 Aug 24. doi: 10.1038/jid.2015.329. [Epub ahead of print] PMID: 26302068

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2015 Jun 15. doi: 10.1038/onc.2015.188. [Epub ahead of print] PMID: 26073081

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290.CD-14-0293. Epub 2014 Dec 26. PMID: 25542447

Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics. 2015 Jan;15(2-3):327-39. doi: 10.1002/pmic.201400200. Epub 2014 Dec 17. PMID: 25339196

Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy? Br J Cancer. 2015 Jan 20;112(2):217-26. doi: 10.1038/bjc.2014.476. Epub 2014 Sep 2. Review. PMID: 25180764

Fedorenko IV, Fang B, Koomen JM, Gibney GT, Smalley KS. Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res. 2014 Oct;24(5):448-53. doi: 10.1097/CMR.0000000000000103. PMID: 24950457